ClinicalTrials.gg
CompletedNCT02189577TrigonUpdated Oct 29, 2021

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

A Phase 2 interventional study of CHF 5259 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 29 sites in 4 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
43rd of 73
100 · median 152
Started
2014
with 8 others
Phase 2
19 of 73
none open now
Registered
42nd of 73
by date
Lead sponsor
13 of 73
Chiesi Farmaceutici S.p.A.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 43rd largest by enrollment, is one of 9 that started in 2014, is one of 19 in phase 2, and was the 42nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.

Read the detailed description

A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary disease
  • COPD
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults (40 ≤ age ≤ 80 years) with a diagnosis of
  • Current smokers or ex-smokers
  • A post-bronchodilator \< 60% of the predicted normal value and a post-bronchodilator FEV1/FVC \< 0.7
  • Positive response to the reversibility test at screening defined as change in FEV1 ≥ 5%.
  • BDI score ≤ 10
  • Patients free of exacerbations for at least 1 month

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of asthma
  • Patients treated for exacerbations in the 4 weeks prior to screening visit
  • Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN
  • Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia
  • Known respiratory disorders other than
  • Patients who have cardiovascular condition
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    CHF 5259

    CHF 5259

    Drug: CHF 5259

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.

    Also known as: glycopyrrolate bromide

  • DrugPlacebo

    Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-dose morning FEV1 on Day 28

    Time frame: Day 28

Secondary outcomes

  1. Change from baseline to day 28 in area under the curve for forced expiratory volume in 1 second measured at 11 timepoints between 0 to 12 hours postdose (FEV1 AUC0-12h)

    Time frame: Day 28

07

Study locations

29 sites
  • Chiesi Clinical Trial Site 1017
    Sevlievo, Bulgaria
  • Chiesi Clinical Trial Site 1010
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 1011
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 1014
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 1015
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 1016
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 1012
    Stara Zagora, Bulgaria
  • Chiesi Clinical Trial Site 1013
    Troyan, Bulgaria
  • Chiesi Clinical Trial Site 2024
    Berlin, Germany
  • Chiesi Clinical Trial Site 2028
    Berlin, Germany
  • Site 2020 - Pulmonary Research Institute at Hospital Grosshansdorf
    Großhansdorf, D-22927, Germany
  • Chiesi Clinical Trial Site 2027
    Hamburg, Germany
  • Chiesi Clinical Trial Site 2026
    Leipzig, Germany
  • Chiesi Clinical Trial Site 2023
    Magdeburg, Germany
  • Chiesi Clinical Trial Site 2021
    Radebeul, Germany
  • Chiesi Clinical Trial Site 2022
    Witten, Germany
  • Chiesi Clinical Trial Site 3039
    Bydgoszcz, Poland
  • Chiesi Clinical Trial Site 3032
    Katowice, Poland
  • Chiesi Clinical Trial Site 3035
    Kraków, Poland
  • Chiesi Clinical Trial Site 3037
    Lubin, Poland
  • Chiesi Clinical Trial Site 3031
    Ostrowiec Świętokrzyski, Poland
  • Chiesi Clinical Trial Site 3033
    Oświęcim, Poland
  • Chiesi Clinical Trial Site 3038
    Rzeszów, Poland
  • Chiesi Clinical Trial Site 3034
    Tarnów, Poland
  • Chiesi Clinical Trial Site 3030
    Wrocław, Poland
  • Chiesi Clinical Trial Site 3036
    Zgierz, Poland
  • Site 4040 - Royal Brompton and Harefield NHS Foundation Trust; South Kensington Campus
    London, SW7 2AZ, United Kingdom
  • Chiesi Clinical Trial Site 4042
    London, United Kingdom
  • Chiesi Clinical Trial Site 4041
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 14, 2014
Start
Jun 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02189577
Responsible party
Sponsor
First posted
Jul 14, 2014
Start date
Jun 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Oct 29, 2021

Study contacts

Michael POLKEY, MD
principal investigator · Royal Brompton and Harefield NHS Foundation Trust; South Kensington Campus, London SW7 2AZ; UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion